Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

Kazuhiro Kamata, Kazuaki Jindai, Nao Ichihara, Hiroki Saito, Hideaki Kato, Hiroyuki Kunishima, Ayumi Shintani, Osamu Nishida, Shigeki Fujitani

研究成果: Letter査読

抄録

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

本文言語English
論文番号34
ジャーナルJournal of Intensive Care
9
1
DOI
出版ステータスPublished - 12-2021

All Science Journal Classification (ASJC) codes

  • 集中医療医学

フィンガープリント

「Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル